Advances in integrative medicine

· 1 paper in corpus
2022
Safety and tolerability of Pau d' Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18-45.
doi:10.1016/j.aimed.2022.04.003 ·PMID:36960315

ObjectivesTo evaluate the safety and tolerability of encapsulated Tabebuia avellanedae in generally healthy women aged 18-45 with primary dysmenorrhea.MethodsA single arm, open-label trial was conducted in which 1050 mg/day of encapsulated …